ethyl 5-ethenylpyridine-2-carboxylate | 1269028-74-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl 5-ethenylpyridine-2-carboxylate
• CAS: 1269028-74-1
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: ZZTINWDLDINYIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 5-ethenylpyridine-2-carboxylate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以100%的产率得到5-Ethylpyridin-2-carbonsaeureethylester
  参考文献：
  名称：

  Synthesis and evaluation of hedgehog signaling inhibitor with novel core system

  摘要：

  As we previously reported, N-methylpyrrolo[3,2-c] pyridine derivatives 1 (TAK-441) was discovered as a clinical candidate of hedgehog (Hh) signaling inhibitor by modification of the upper part. We next focused on modification of the lower part including core skeletons to discover new Hh signaling inhibitors with novel core rings. Efforts to find novel chemotypes by using X-ray single crystal structure analysis led to some potent Hh signaling inhibitors (2c, 2d, 2e, 2f) with novel core ring systems, which had benzamide moiety at the 5-position as a key component for potent activity. The suppression of Gli1 expression with these new Hh signaling inhibitors were weaker than that of compound 1 (TAK-441) because of low pharmacokinetic property. We recognized again TAK-441 is a good compound as clinical candidate with good structural and pharmacokinetic advantages. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.036
• 作为产物：
  描述：

  5-溴-2-吡啶羧酸 在 四(三苯基膦)钯 硫酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 ethyl 5-ethenylpyridine-2-carboxylate
  参考文献：
  名称：

  FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF

  摘要：

  公开号：

  EP2471789B9

文献信息

• US8486965B2
  申请人：——

  公开号：US8486965B2

  公开（公告）日：2013-07-16
• [EN] NOVEL 4-AMINOPIPERIDINE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE 4-AMINOPIPERIDINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2006056930A2

  公开（公告）日：2006-06-01

  [EN] Novel substituted 4-aminopiperidine derivatives of the formula I: wherein n, R¹ , Y, (A) , and (B) are as defined in claim 1 and optically pure enantiomers, mixtures of enantiomers, racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and meso-forms, as well as salts and solvent complexes of such compounds, and morphological forms, that exhibit useful parasite aspartic proteases inhibiting properties and can thus be used in the form of pharmaceutical compositions as antimalarial medicines.
  [FR] L'invention concerne de nouveaux dérivés de 4-aminopipéridine substitués de formule I, dans laquelle n, R¹, Y, (A) et (B) sont tels que définis dans la revendication 1, ainsi que des énantiomères optiquement purs, des mélanges d'énantiomères, des racémates, des diastéréomères, des mélanges de diastéréomères, des racémates diastéréomériques, des mélanges de racémates diastéréomériques et des formes méso, ainsi que des sels et des complexes de solvants desdits composés, et des formes morphologiques, présentant des propriétés utiles inhibitrices de protéases aspartiques parasitaires et pouvant ainsi être utilisés sous la forme de compositions pharmaceutiques en tant qu'antipaludiques.
• FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2471789B9

  公开（公告）日：2015-03-25
• Synthesis and evaluation of hedgehog signaling inhibitor with novel core system
  作者：Tomohiro Ohashi、Yuta Tanaka、Zenyu Shiokawa、Hiroshi Banno、Toshio Tanaka、Sachio Shibata、Yoshihiko Satoh、Hiroko Yamakawa、Yukiko Yamamoto、Harumi Hattori、Shigeru Kondo、Maki Miyamoto、Hideaki Tojo、Atsuo Baba、Satoshi Sasaki

  DOI：10.1016/j.bmc.2015.05.036

  日期：2015.8

  As we previously reported, N-methylpyrrolo[3,2-c] pyridine derivatives 1 (TAK-441) was discovered as a clinical candidate of hedgehog (Hh) signaling inhibitor by modification of the upper part. We next focused on modification of the lower part including core skeletons to discover new Hh signaling inhibitors with novel core rings. Efforts to find novel chemotypes by using X-ray single crystal structure analysis led to some potent Hh signaling inhibitors (2c, 2d, 2e, 2f) with novel core ring systems, which had benzamide moiety at the 5-position as a key component for potent activity. The suppression of Gli1 expression with these new Hh signaling inhibitors were weaker than that of compound 1 (TAK-441) because of low pharmacokinetic property. We recognized again TAK-441 is a good compound as clinical candidate with good structural and pharmacokinetic advantages. (C) 2015 Elsevier Ltd. All rights reserved.